UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Medline ® Abstract for Reference 9

of 'Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders'

9
TI
Omeprazole. Overview and opinion.
AU
Holt S, Howden CW
SO
Dig Dis Sci. 1991;36(4):385.
 
Omeprazole, a substituted benzimidazole, is a specific inhibitor of the enzyme H+/K(+)-ATPase, which is found on the secretory surface of the parietal cell. This enzyme, the "proton pump," catalyzes the final step in acid secretion. Omeprazole is a powerful inhibitor of gastric acid secretion. At the time of writing, omeprazole has been licensed in the United States for the treatment of severe grades of gastroesophageal reflux disease (GERD) as well as GERD unresponsive to treatment with currently available agents, and for the treatment of Zollinger-Ellison syndrome and other gastric hypersecretory states. Most recently, it has been recommended by the FDA advisory committee for approval as first-line therapy in duodenal ulcer disease.
AD
Division of Digestive Diseases and Nutrition, University of South Carolina School of Medicine, Columbia.
PMID